Susanne Temming1, Martin Kocher2, Erich Stoelben3, Lars Hagmeyer4, De-Hua Chang5, Konrad Frank6, Khosro Hekmat7, Juergen Wolf8, Wolfgang W Baus1, Robert Semrau1, Christian Baues1, S Marnitz1. 1. Department of Radiation Oncology, Center for Integrated Oncology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. 2. Department of Radiation Oncology, Center for Integrated Oncology, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. martin.kocher@uk-koeln.de. 3. Lung Clinic Merheim, Hospital of Cologne, Cologne, Germany. 4. Bethanien Hospital, Institute of Pneumology, University of Cologne, Solingen, Germany. 5. Department of Diagnostic and Interventional Radiology, Center for Integrated Oncology, University of Cologne, Cologne, Germany. 6. Department III of Internal Medicine, Heart Centre of the University of Cologne, Cologne, Germany. 7. Department of Cardiothoracic Surgery, Center for Integrated Oncology, University of Cologne, Cologne, Germany. 8. First Department of Internal Medicine, Center for Integrated Oncology, University Hospital of Cologne, Cologne, Germany.
Abstract
PURPOSE: To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients. METHODS: From 2012 to 2016, 106 patients (median age 74 years, range 50-94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent 18F-fluorodeoxyglucose positron-emission tomography (18-FDG-PET) and/or endobronchial ultrasound (EBUS)-guided lymph node biopsy or mediastinoscopy. Tumor stage (UICC8, 2017) was IA/B (T1a-c, 1-3 cm) in 86 patients (81%) and IIA (T2a/b, 3-5 cm) in 20 patients (19%). Depending on tumor localization, three different fractionation schedules were used: 3 fractions of 17Gy, 5 fractions of 11Gy, or 8 fractions of 7.5 Gy. Tracking was based on fiducial implants in 13 patients (12%) and on image guidance without markers in 88%. RESULTS: Median follow-up was 15 months (range 0.5-46 months). Acute side effects were mild (fatigue grade 1-2 in 20% and dyspnea grade 1-2 in 17%). Late effects were observed in 4 patients (4%): 3 patients developed pneumonitis requiring therapy (grade 2) and 1 patient suffered a rib fracture (grade 3). In total, 9/106 patients (8%) experienced a local recurrence, actuarial local control rates were 88% (95% confidence interval, CI, 80-96%) at 2 years and 77% (95%CI 56-98%) at 3 years. The median disease-free survival time was 27 months (95%CI 23-31 months). Overall survival was 77% (95%CI 65-85%) at 2 years and 56% (95%CI 39-73%) at 3 years. CONCLUSION: CyberKnife® lung SBRT which allows for real-time tumor tracking and risk-adapted fractionation achieves satisfactory local control and low toxicity rates in inoperable early-stage primary lung cancer patients.
PURPOSE: To evaluate efficacy and toxicity of stereotactic body radiation therapy (SBRT) with CyberKnife® (Accuray, Sunnyvale, CA, USA) in a selected cohort of primary, medically inoperable early-stage non-small cell lung cancer (NSCLC) patients. METHODS: From 2012 to 2016, 106 patients (median age 74 years, range 50-94 years) with primary NSCLC were treated with SBRT using CyberKnife®. Histologic confirmation was available in 87 patients (82%). For mediastinal staging, 92 patients (87%) underwent 18F-fluorodeoxyglucose positron-emission tomography (18-FDG-PET) and/or endobronchial ultrasound (EBUS)-guided lymph node biopsy or mediastinoscopy. Tumor stage (UICC8, 2017) was IA/B (T1a-c, 1-3 cm) in 86 patients (81%) and IIA (T2a/b, 3-5 cm) in 20 patients (19%). Depending on tumor localization, three different fractionation schedules were used: 3 fractions of 17Gy, 5 fractions of 11Gy, or 8 fractions of 7.5 Gy. Tracking was based on fiducial implants in 13 patients (12%) and on image guidance without markers in 88%. RESULTS: Median follow-up was 15 months (range 0.5-46 months). Acute side effects were mild (fatigue grade 1-2 in 20% and dyspnea grade 1-2 in 17%). Late effects were observed in 4 patients (4%): 3 patients developed pneumonitis requiring therapy (grade 2) and 1 patient suffered a rib fracture (grade 3). In total, 9/106 patients (8%) experienced a local recurrence, actuarial local control rates were 88% (95% confidence interval, CI, 80-96%) at 2 years and 77% (95%CI 56-98%) at 3 years. The median disease-free survival time was 27 months (95%CI 23-31 months). Overall survival was 77% (95%CI 65-85%) at 2 years and 56% (95%CI 39-73%) at 3 years. CONCLUSION: CyberKnife® lung SBRT which allows for real-time tumor tracking and risk-adapted fractionation achieves satisfactory local control and low toxicity rates in inoperable early-stage primary lung cancerpatients.
Authors: Robert Timmerman; Rebecca Paulus; James Galvin; Jeffrey Michalski; William Straube; Jeffrey Bradley; Achilles Fakiris; Andrea Bezjak; Gregory Videtic; David Johnstone; Jack Fowler; Elizabeth Gore; Hak Choy Journal: JAMA Date: 2010-03-17 Impact factor: 56.272
Authors: Conrad B Falkson; Emily T Vella; Edward Yu; Medhat El-Mallah; Robert Mackenzie; Peter M Ellis; Yee C Ung Journal: Clin Lung Cancer Date: 2016-10-27 Impact factor: 4.785
Authors: Joe Y Chang; Suresh Senan; Marinus A Paul; Reza J Mehran; Alexander V Louie; Peter Balter; Harry J M Groen; Stephen E McRae; Joachim Widder; Lei Feng; Ben E E M van den Borne; Mark F Munsell; Coen Hurkmans; Donald A Berry; Erik van Werkhoven; John J Kresl; Anne-Marie Dingemans; Omar Dawood; Cornelis J A Haasbeek; Larry S Carpenter; Katrien De Jaeger; Ritsuko Komaki; Ben J Slotman; Egbert F Smit; Jack A Roth Journal: Lancet Oncol Date: 2015-05-13 Impact factor: 41.316
Authors: Matthias Guckenberger; Rainer J Klement; Michael Allgäuer; Nicolaus Andratschke; Oliver Blanck; Judit Boda-Heggemann; Karin Dieckmann; Marciana Duma; Iris Ernst; Ute Ganswindt; Peter Hass; Christoph Henkenberens; Richard Holy; Detlef Imhoff; Henning K Kahl; Robert Krempien; Fabian Lohaus; Ursula Nestle; Meinhard Nevinny-Stickel; Cordula Petersen; Sabine Semrau; Jan Streblow; Thomas G Wendt; Andrea Wittig; Michael Flentje; Florian Sterzing Journal: Radiother Oncol Date: 2015-09-15 Impact factor: 6.280
Authors: M Essler; J Wantke; B Mayer; K Scheidhauer; R A Bundschuh; B Haller; S T Astner; M Molls; N Andratschke Journal: Strahlenther Onkol Date: 2013-04-24 Impact factor: 3.621
Authors: M Guckenberger; N Andratschke; H Alheit; R Holy; C Moustakis; U Nestle; O Sauer Journal: Strahlenther Onkol Date: 2013-09-21 Impact factor: 3.621
Authors: Oren B Factor; Charles C Vu; Jeffrey G Schneider; Matthew R Witten; Scott L Schubach; Alicia E Gittleman; Donna T Catell; Jonathan A Haas Journal: Front Oncol Date: 2014-10-20 Impact factor: 6.244
Authors: Franz Zehentmayr; Martin Sprenger; Lukas Rettenbacher; Romana Wass; Peter Porsch; Gerd Fastner; Christian Pirich; Michael Studnicka; Felix Sedlmayer Journal: Thorac Cancer Date: 2019-01-07 Impact factor: 3.500
Authors: Khaled Bousabarah; Oliver Blanck; Susanne Temming; Maria-Lisa Wilhelm; Mauritius Hoevels; Wolfgang W Baus; Daniel Ruess; Veerle Visser-Vandewalle; Maximilian I Ruge; Harald Treuer; Martin Kocher Journal: Radiat Oncol Date: 2021-04-16 Impact factor: 3.481
Authors: Rene Baumann; Mark K H Chan; Florian Pyschny; Susanne Stera; Bettina Malzkuhn; Stefan Wurster; Stefan Huttenlocher; Marcella Szücs; Detlef Imhoff; Christian Keller; Panagiotis Balermpas; Dirk Rades; Claus Rödel; Jürgen Dunst; Guido Hildebrandt; Oliver Blanck Journal: Front Oncol Date: 2018-05-17 Impact factor: 6.244